An experimental medication slows the progression of the neurodegenerative disease called Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, according to recently released results from a clinical trial.Learn More
Sean M. Healey & AMG Center for ALS
News & Events
Recent Media CoverageView All
Mass. General will lead the simultaneous testing of multiple potential treatments for the deadly disease.
Aural Analytics’ speech-based digital technology will be used to measure changes in speech in people with amyotrophic lateral sclerosis (ALS) as endpoints for the HEALEY ALS Platform Trial, which is evaluating multiple potential ALS treatments simultaneously.
Aural Analytics To Power Speech-Based Endpoints For The Healey Center ALS Platform Trial at Mass General Hospital
Aural Analytics’ award-winning clinical trials platform will provide speech collection and speech-based digital endpoints for the HEALEY ALS Platform trial study regimens
Make a Difference for the Healey Center
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.